|
|
|
| Trend in disease burden of interstitial lung disease in China from 1990 to 2021 |
| SUN Yuefeng1, GUO Sijia2, WEI Yuan3, HE Tiantian1, GUO An1, ZENG Zhaolu1, SUN Luyan1, DOU Wenjing1, SUN Zengtao4
|
1. Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China;
2. The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China;
3. Tianjin Integrated Traditional and Western Medicine Hospital, Tianjin 300074, China;
4. College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China |
|
|
|
|
Abstract Objective To investigate the trend in disease burden of interstitial lung disease (ILD) in China from 1990 to 2021, so as to provide a reference for formulating prevention and control strategies for chronic respiratory diseases. Methods Based on the Global Burden of Disease 2021 database, data on the number of incident cases, incidence, standardized incidence, number of deaths, mortality, standardized mortality, number of disability-adjusted life years (DALY), DALY rate, and standardized DALY rate of ILD in China were collected. The incidence, mortality, and DALY rate were used to analyze the disease burden of ILD. The estimated annual percentage change (EAPC) was employed to assess the trend in standardized incidence, standardized mortality, and standardized DALY rate of ILD from 1990 to 2021. Rate decomposition analysis was applied to identify the main contributing factors affecting the trend in disease burden. Results In 2021, China reported 48 514 cases, 7 674 deaths, and 222 288 person-years of DALY due to ILD, representing increases of 155.43%, 159.70%, and 97.34%, respectively, compared with 1990. From 1990 to 2021, the standardized incidence and standardized mortality of ILD in China showed upward trends (EAPC=1.106% and 0.239%, both P<0.05), while the standardized DALY rate showed a downward trend (EAPC=-0.230%, P<0.05). From 1990 to 2021, the standardized incidence and standardized mortality among males showed upward trends (EAPC=1.199% and 0.520%, both P<0.05), while the trend in the standardized DALY rate was not statistically significant (P>0.05). Among females, the standardized incidence of ILD showed an upward trend (EAPC=0.966%, P<0.05), while the standardized mortality and standardized DALY rate showed downward trends (EAPC=-0.306% and -0.760%, both P<0.05). In 2021, the incidence, mortality, and DALY rate of ILD in China increased with age, peaking in the group aged ≥95 years at 14.84/105, 13.90/105, and 124.71/105, respectively. Across all age groups aged ≥55 years, the incidence, mortality, and DALY rate of ILD were consistently higher in males than in females. The increase in the number of incident cases, deaths, and DALY due to ILD in China from 1990 to 2021 was primarily influenced by population aging, with contribution rates of 42.65%, 68.25%, and 69.79%, respectively. Conclusions From 1990 to 2021, the incidence and mortality risk of ILD in China showed upward trends, while the disability risk demonstrated a downward trend. Males bore a heavier disease burden of ILD, and aging was identified as the primary factor contributing to the increased burden of ILD in China.
|
|
Received: 01 July 2025
Revised: 22 October 2025
Published: 20 November 2025
|
|
|
|
|
|
[1] MAHRE T M.Interstitial lung disease:a review[J].JAMA,2024,331(19):1655-1665.
[2] ALGAMDI M,SADATSAFAVI M,FISHER J H,et al.Costs of workplace productivity loss in patients with connective tissue disease-associated interstitial lung disease[J].Ann Am Thorac Soc,2020,17(9):1077-1084.
[3] 罗进斌,何晓庆,陈强,等.金华市244例职业性尘肺病患者生存质量调查[J].预防医学,2023,35(6):517-521.
LUO J B,HE X Q,CHEN Q,et al.Quality of life among 244 patients with occupational pneumoconiosis in Jinhua City[J].China Prev Med J,2023,35(6):517-521.(in Chinese)
[4] MA X Q,ZHU L L,KURCHE J S,et al.Global and regional burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2019:results from the Global Burden of Disease study 2019[J].Thorax,2022,77(6):596-605.
[5] GBD Chronic Respiratory Disease Collaborators.Prevalence and attributable health burden of chronic respiratory diseases,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet Respir Med,2020,8(6):585-596.
[6] CHEN S H,LI Y L.Global health inequalities in the burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2021[J].BMC Public Health,2024,24(1):1-7.
[7] ZHAI Y,ZHU C M,ZHU T X,et al.Global,regional,and national burden of chronic respiratory diseases,1990-2021 and predictions to 2035:analysis of data from the global burden of disease study 2021[J].Ann Med,2025,57(1):1-25.
[8] DAS G P.A general method of decomposing a difference between two rates into several components[J].Demography,1978,15(1):99-112.
[9] GBD 2019 Chronic Respiratory Diseases Collaborators.BD 2019 Chronic Respiratory Diseases Collaborators.Global burden of chronic respiratory diseases and risk factors,1990-2019:an update from the Global Burden of Disease Study 2019[J/OL].EClinicalMedicine,2023,59[2025-10-22].https://doi.org/10.1016/j.eclinm.2023.101936.
[10] GOOBIE G C,CARLSTEN C,JOHANNSON K A,et al.Association of particulate matter exposure with lung function and mortality among patients with fibrotic interstitial lung disease[J].JAMA Intern Med,2022,182(12):1248-1259.
[11] 杭文璐,武琦,李婉君,等.SiO2对大鼠气道表面微环境和NEK7/NLRP3炎性小体的影响研究[J].预防医学,2023,35(2):180-184.
HANG W L,WU Q,LI W J,et al.Effect of silicon dioxide exposure on airway surface microenvironment and NEK7/NLPR3 inflammasome in rats[J].China Prev Med J,2023,35(2):180-184.(in Chinese)
[12] PODOLANCZUK A J,WONG A W,SAITO S,et al.Update in interstitial lung disease 2020[J].Am J Respir Crit Care Med,2021,203(11):1343-1352.
[13] MURGIA N,AKGUN M,BLANC P D,et al.Issue 3:the occupational burden of respiratory diseases,an update[J/OL].Pulmonology,2025,31(1)[2025-10-22].https://doi.org/10.1016/j.envint.2020.106272.
[14] 王苑颖,叶俏.抗肺纤维化药物研究进展[J].中国药理学与毒理学杂志,2025,39(2):146-160.
WANG Y Y,YE Q.Current research and development of anti-pulmonary fibrosis drugs[J].Chin J Pharmacol Toxicol,2025,39(2):146-160.(in Chinese)
[15] LUPPI F,KALLURI M,FAVERIO P,et al.Idiopathic pulmonary fibrosis beyond the lung:understanding disease mechanisms to improve diagnosis and management[J/OL].Respir Res,2021,22(1)[2025-10-22].https://doi.org/109.10.1186/s12931-021-01711-1.
[16] GULER S A,CORTE T J.Interstitial lung disease in 2020:a history of progress[J].Clin Chest Med,2021,42(2):229-239.
[17] MONTESI S B,FISHER J H,MARTINEZ F J,et al.Update in interstitial lung disease 2019[J].Am J Respir Crit Care Med,2020,202(4):500-507.
[18] SELMAN M,PARDO A.When things go wrong:exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases[J/OL].Eur Respir J,2021,58(3)[2025-10-22].https://doi.org/10.1183/13993003.04507-2020.
[19] LEE S C,HUANG C H,OYANG Y J,et al.Macrophages as determinants and regulators of systemic sclerosis-related interstitial lung disease[J].J Transl Med,2024,22(1):1-11.
[20] 汪伟,王春超.人口转变、人口红利与人口老龄化[J].浙江社会科学,2025(4):4-18,41,156.
WANG W,WANG C C.Demographic transition,demographic dividend and population aging[J].Zhejiang Soc Sci,2025(4):4-18,41,156.(in Chinese) |
|
|
|
